DT05 Rec'd PCT/PT0 0 8 DEC 2004

Attorney Docket No. B45311

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/EP03/06096	06 June 2003	11 June 2002						
TITLE OF INVENTION								
IMMUNOGENIC COMPOSITIONS								
	-							
APPLICANT(S) FOR DO/US								
CABEZON SILIVA, Teres	sa, Elisa Virginia; ELLIS, Jonat	han H.; GERARD, Catherine						
Marie, Ghislaine; HAMBLIN, Paul A.; PALMANTIER, Remi, M.; and VINALS Y DE								
PASSOIS Corloto								

FILING OF AN INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[X] A copy of the International Se	earch Report, which issued on International Application No.						
PCT/EP03/06096	is submitted herewith. All of the publications cited in the						
International Search Report are listed on the attached form PTO-1449 and Applicants							
understand that copies have b	een supplied to the U.S. Patent Office by the International						
Bureau.	·						

[] Copies of references not listed on the International Search Report are enclosed.

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted

Andrea V. Lockenour Attorney for Applicants Registration No. 51,962

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-7568 Facsimile (610) 270-5090



DT05 Rec'd PCT/PTO 058-DEC-2004

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office			ATTY, DOCKET NO. B45311		INTERNATIONAL APPLICATION NO. PCT/EP03/06096						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			Jonathan H.; GERAF HAMBLIN, Paul A.;	ABEZON SILIVA, Teresa, Elisa Virginia; ELLIS, onathan H.; GERARD, Catherine Marie, Ghislaine; AMBLIN, Paul A.; PALMANTIER, Remi, M.; ad VINALS Y DE BASSOLS, Carlota ING DATE GROUP							
	 		IIS D	ATENT I	OOCUMENTS						
Examiner Initial		Document Number	Date Date	Name		Class	Subclass	Subclass Filing I			
	AA	6,090,388	18 July 2000	Wang	Chang Yi						
			FOREIGN	J PATEN	IT DOCUMENTS						
		Document Number	Date	T A I E	Country	Class	Subclass	<u>Trans</u> Yes	lation No		
	BA	WO9967293A	29 Dec 1999	PCT							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
	CA	Sanchez-Puelles, J. M. et al., "Immobilization and single-step purification fusion proteins using DEAE-cellulose," <i>Eur. J. Biochem</i> (1992) 203(1-2): 153-160 (XP-001155694).									
	СВ	Caugin, J. et al., "Choline-Binding Domain as a Novel Affinity Tag fur Purification of Fusion Proteins Produced in <i>Pichia pastoris</i> ," <i>Biotechnology and Bioengineering</i> (July 2001) 74(2): 164-171 (XP-001155696).									
	CC	Kjerrulf, M. et al., "Tandem Repeats of T Helper Epitopes Enhance Immunogenicity of Fusion Proteins by Promoting Processing and Presentation," <i>Molecular Immunology</i> (June 1997) 34(8/9): 599-608 (XP-000857056).									
	CD	Astori, M. et al., "Recombinant Fusion Peptides Containing Single or Multiple Repeats of a Ubiquitous T-Helper Epitope are Highly Immunogenic," <i>Molecular Immunology</i> (1996)33(13): 1017-1024 (XP-001028964).									
	CE	Olszewska, Wieslawa et al., "Protection against Measles Virus-Induced Encephalitis by Antimimotope Antibodies: The Role of Antibody Affinity," <i>Virology</i> (30 June 2000) 272(1): 98-105 (XP-002259121)									
EXAMINER			DATE CONSIDERED								
·EXAMINE	R: Initic	al if citation consider	ed, whether or n	ot citati	on is in conformance wit	h MPEP	609; Draw line	through	\neg		
citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											